About EsoBiotec
EsoBiotec is a Healthcare company based in Mont-saint-guibert (Belgium) founded in 2020 by Jean-Pierre Latere, and was acquired by Astrazeneca in March 2025. EsoBiotec has raised $2.15 million across 2 funding rounds from investors including Astrazeneca, Invivo Partners and UCB Ventures. The company has 8 employees. Its chief executive, as recorded, is Jean-Pierre Latere. EsoBiotec offers products and services including ENaBL Vector Platform and Off-the-Shelf Therapies. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
EsoBiotec was founded in 2020 within the biotechnology sector, where in vivo adoptive cell therapies for cancer and autoimmune diseases are developed. Immune cells are engineered directly in patients to avoid ex vivo manufacturing complexities. A proprietary vector platform is employed for single-injection, off-the-shelf treatments that minimize rejection risks and enable scalable, high-yield production. Operations focus on simplifying logistics and improving accessibility through reduced costs.
- Headquarters Mont-saint-guibert, Belgium
- Employees 8
- Founders Jean-Pierre Latere
- Stage Acquired
- SectorsHealthcare
- Website esobiotec.com
- Social LinkedIn
- Acquired by Astrazeneca (Mar 2025)
- Legal Name Esobiotec
- Net Profit-$1.06 M (USD)-406as on Dec 31, 2022
- EBITDA$1.53 M (USD)898as on Dec 31, 2022
- Total Equity Funding$2.15M (USD)
in 2 rounds
- Latest Funding Round$2.15M (USD), Series A
Dec 2023
- InvestorsAstrazeneca
& 5 more
- Employee Count8
- Acquired byAstrazeneca
(Mar 2025)
Products & Services of EsoBiotec
EsoBiotec offers a comprehensive portfolio of products and services, including ENaBL Vector Platform and Off-the-Shelf Therapies.
Enables in vivo cell therapies for cancer treatment and disease management.
Provides immune-shielded treatments for solid tumors and autoimmune conditions.
Funding Insights of EsoBiotec
EsoBiotec has successfully raised a total of $2.15M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.15 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.15M
- Total Rounds 2
- Last Round Series A — $2.15M
- Investors Count 5
All 2 funding rounds of EsoBiotec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $2.15M | Series A | – | Invivo Partners | – |
| Jun 2021 | Seed | – | UCB Ventures, Thuja Capital | – |
6 investors in total: 6 institutional.
Investors in EsoBiotec
EsoBiotec has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, Invivo Partners and UCB Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Invivo Partners is engaged in venture capital investments for early-stage healthcare companies. | invivo.partners | Barcelona, Spain | ||
UCB Ventures is focused on strategic corporate venture investments. | 2017 | ucbventures.com | Brussels, Belgium | |
Early-stage centric life sciences focused VC firm funding in Netherlands, Belgium and the US | thujacapital.com | Utrecht, Netherlands | ||
VC & PE fund | sambrinvest.be | Charleroi, Belgium | ||
| wallonie-entreprendre.be | ||||
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for EsoBiotec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EsoBiotec
1 people are tracked at EsoBiotec (1 in leadership); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Jean-Pierre Latere | Founder & CEO | Leadership |
Complete people profiles for EsoBiotec
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EsoBiotec
4 dated milestones of EsoBiotec across 5 years, from founding to its latest funding, stage changes and deals.
- Founded EsoBiotec is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $2.2M.
- Exit Acquired by Astrazeneca.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Esobiotec
Complete news archive for EsoBiotec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EsoBiotec
EsoBiotec was founded in 2020 and raised its 1st funding round 1 year after it was founded.
EsoBiotec is headquartered in Mont-saint-guibert, Belgium.
Jean-Pierre Latere is the CEO of EsoBiotec, as recorded in our data. They have also founded this company.
EsoBiotec is a funded company, having raised a total of $2.15M across 2 funding rounds to date.
EsoBiotec has 8 employees.
EsoBiotec was founded in 2020 within the biotechnology sector, where in vivo adoptive cell therapies for cancer and autoimmune diseases are developed. Immune cells are engineered directly in patients to avoid ex vivo manufacturing complexities. A proprietary vector platform is employed for single-injection, off-the-shelf treatments that minimize rejection risks and enable scalable, high-yield production. Operations focus on simplifying logistics and improving accessibility through reduced costs.
EsoBiotec offers ENaBL Vector Platform and Off-the-Shelf Therapies.
EsoBiotec has 6 investors. Key investors include Astrazeneca, Invivo Partners, UCB Ventures, Thuja Capital, and Sambrinvest.
EsoBiotec operates through Esobiotec.
Yes. EsoBiotec was acquired by Astrazeneca in March 2025.